ClearPoint Neuro, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; unaudited. ClearPoint Neuro is a commercial-stage medical-device company focused on minimally invasive brain procedures and related services for drug-delivery and therapy partners.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $5.95m | $5.20m | $11.38m | $10.23m |
| Gross profit / margin | $3.13m / 53% | $3.26m / 63% | $6.33m / 56% | $6.49m / 63% |
| Operating loss | $(7.13)m | $(4.20)m | $(12.84)m | $(8.07)m |
| Net loss | $(7.05)m | $(4.30)m | $(12.66)m | $(8.26)m |
| Net loss per share | $(0.29) | $(0.18) | $(0.52) | $(0.35) |
- Q2 product revenue fell 32% to $2.34m, while service and other revenue rose 107% to $3.61m. For the first half, product revenue fell 25% to $4.97m and service and other revenue increased 78% to $6.42m.
- Biologics and drug-delivery revenue increased 40% in Q2 to $3.37m and 32% in the first half to $6.04m, mainly from services, pre-clinical work and license fees. Capital equipment and software revenue declined 38% in both periods, attributed primarily to fewer system placements.
- Gross margin contracted as a greater share of revenue came from lower-margin pre-clinical services and due to costs associated with the manufacturing-facility transition. R&D, sales and marketing, and G&A expenses all increased year over year.
Financial position and cash flow
- At June 30, cash and cash equivalents were $26.46m, with no short-term investments remaining; total current assets were $40.71m and current liabilities $6.20m. Total assets were $47.64m and stockholders’ equity $27.41m.
- Operating cash use was $10.76m for the first half, versus $9.25m a year earlier. Investing activities provided $9.37m, largely from maturity of short-term investments; financing activities provided $0.23m. Cash declined $1.15m from year-end.
- The company reported $10.0m principal outstanding on a secured convertible note, with a $9.92m net carrying amount, due January 2025. The note was convertible at the holder’s option at $6.00 per share and bore a 7.5% rate at June 30. A July 31 amendment replaced LIBOR-based terms with SOFR-based terms.
- A Carlsbad manufacturing-facility lease commenced in June 2023, adding approximately $2.5m in right-of-use assets and lease liabilities. The filing states minimum lease payments for that facility total $5.1m.
Outlook, risks and notable items
- Management said current cash and cash equivalents, based on its forecasts, should support operations and obligations for at least the next 12 months. The filing provides no specific revenue, earnings or profitability guidance.
- Management expects sales and marketing costs to continue increasing with commercialization and headcount; R&D spending may also rise as product development and platform expansion continue. The company has accumulated losses of $163.0m and states it may continue to incur operating losses.
- Risks highlighted include inflation, supply-chain and labor disruption, funding availability, customer adoption and collections, clinical and regulatory uncertainty, reliance on partners and key suppliers, and competition. Three customers represented 24%, 12% and 11% of accounts receivable at period-end; a related-party pharmaceutical customer contributed 12% of Q2 sales. Approximately $1.6m in bank balances exceeded FDIC-insured limits.
- The company reported no known legal matter expected to have a material adverse effect, no material changes to previously disclosed risk factors other than uninsured-deposit exposure, and effective disclosure controls as of June 30.
Important facts for investors to verify
- Whether growth in partner-related service and license revenue can persist and translate into higher-margin, recurring product revenue.
- Whether gross margins recover as the new manufacturing facility transition progresses and the service mix evolves.
- Cash burn and the basis for management’s stated minimum 12-month liquidity outlook, particularly if operating losses or investment needs increase.
- Note interest costs, maturity and potential dilution from conversion; also monitor lease costs and the related-party customer relationship.
- Customer and receivables concentration, uninsured bank deposits, and the effects of clinical, regulatory, supply-chain and partner-commercialization risks.